GPT and cryohydrocytosis: As evidenced by the smaller AICc and BIC values of the TACR testing criteria, incorporating these factors into the treatment eligibility criteria can help better predict the occurrence of Grades 2–4 laboratory abnormalities in ALT/AST/BIL(T) in CHC patients receiving simplified pan-genotypic treatment than the AASLD-IDSA criteria (as well as the EASL criteria) (Table 5).